Kopfbereich

Nacházíte se zde:

Zpravodajské středisko AOP


Tato část našich stránek poskytuje obecné informace o společnosti AOP Orphan. Country manager Veronika Chicevičová (Šárka Reitlerová v zastoupení) Vám ráda odpoví na všechny případné dotazy nebo komentáře:

MUDr. Veronika Chicevičová/ PharmDr. Šárka Reitlerová
AOP Orphan Pharmaceuticals AG
Pod Děvínem 28
150 00 Praha 5
Česká republika
Tel +420 251 512 947
Fax +420 251 512 946
office.cz(at)aoporphan.com

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

Long-term maintenance treatment of Polycythemia Vera (PV) patients with Ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious and well toleratedHome self-administration of individual doses with a pen is well...

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently...

Dr. Rudolf Widmann, výkonný ředitel (CEO) a Dr. Christoph Klade, vědecký ředitel (CSO) poskytli rozhovor o závazku firmy AOP Orphan k průběžné inovaci ve prospěch pacientů se vzácnými onemocněními. Rakouské výzkumné centrum bylo...

The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specializes in rare diseases, has appointed Miroslaw Jan Lubecki MD, MBA to join the management team as Chief of Commercial Operations.

EMA started the centralized marketing authorization procedure for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) on Feb 23rd 2017.
Ropeginterferon alfa-2b is a novel mono-pegylated interferon with an improved...

At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) PROUD-PV demonstrated a significantly better safety and tolerability profile of ropeginterferon...

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

Dr Roland Bindeus (38) took control of the Hematology & Oncology Business Unit at the Austrian pioneer of rare diseases, AOP Orphan, at the beginning of April. The biochemist was most recently the general manager of Baxalta...

The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specialises in rare diseases, has appointed Suzie McFadzean to join the management team as Chief of Commercial Operations. British-born Suzie...

AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member...

Today AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, announced the creation of Rigi Orphan Inc, USA.  The new company will focus on the development, in-licensing and commercialization of...

INDIANAPOLIS, IN — CONFLUENCE PHARMACEUTICALS and AOP Orphan Pharmaceuticals AG (“AOP”), announced today they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the two special preparations by the highly innovative, publicly listed company Cardiome Pharma...

The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market. This means that the drug,...

01.10.2014:

LOJUXTA™

Biopharmaceutická společnost Aegerion Pharmaceuticals, Inc. oznámila 1.8.2013 schválení EMEA jejich nově vyvinuté molekuly lomitapid, LOJUXTA™, k léčbě pacientů s homozygotní familiární hypercholesterolémií.

01.10.2014:

Tetmodis® 25 mg

Přípravek Tetmodis® je registrován k léčbě hyperkinetických pohybových poruch s Huntingtonovou choreou a je k dispozici v České republice od roku 2011. Od 1.5.2014 je Tetmodis® hrazen zdravotní pojišťovnou.  Pro další...

Společnosti AOP Orphan a Ferrer Internacional rozšiřují své dlouhodobé partnerství a uvádějí společně na trhy ve střední a východní Evropě antipsychotikum Adasuve® (Staccato® loxapine)

01.10.2014:

Adasuve®

Adasuve

Od 20.února 2013 je v České republice zaregistrován přípravek ADASUVE®, nové antipsychotikum v unikátní inhalační formě.

Rakouská farmaceutická společnost AOP Orphan, která se specializuje na vzácná onemocnění a inovativní terapie, uvedla na trh ve střední Evropě lék na léčbu fibrilace síní BRINAVESS®, který vyvinula kanadská společnost Cardiome...

07.04.2014:

Brinavess®

Od 7.4.2014 je v ČR k dispozici přípravek Brinavess® 20 mg/ml inf.cnc.sol.1x25 ml.

Od 9.10.2013 je znovu k dispozici na českém trhu přípravek Esmocard 2500 mg/10 ml, který byl v rámci specifického léčebného programu od 1.12.2013 do 9.10.2013 dočasně nahrazen přípravkem Esmolol Amomed. Přípravek Esmocard 2500...

Dne 18.10.2012 došlo k dočasnému přerušení dodávek léčivého přípravku Esmocard 2500 MG/10 ML koncentrát pro přípravu infuzního roztoku na český trh. Přípravek Esmocard 2500 MG/10 ML  byl z důvodu zajištění dostupnosti...

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

In order to add impetus to the rapid expansion of recent years, the Austrian pharmaceutical company AOP Orphan is strengthening its management team.

AOP Orphan Pharmaceuticals has been awarded the exclusive distributions rights for Brinavess® (vernakalant) by Cardiome Pharma Corporation for most Central and Eastern European countries, as well as for Switzerland and Austria....

The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management experience to become CFO.

AOP Orphan Pharmaceuticals AG today announced the spin off of its 80 % stake in Activartis GmbH, a Vienna-based biotech company with a strong platform for immune-based cancer vaccines, to a group of private investors. The...

Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b...

A documentary on living with rare diseases; by Edith Bachkönig (currently available in German only)

At AOP Orphan are European pioneers in the field of Orphan Diseases. We research, develop, produce, and distribute innovative solutions for Rare Diseases worldwide.

With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian...